Academic Journal
Efficacy of 'Triple Therapy' in Eradicating Ulcer Related Helicobacter pylori Infection at a Tertiary Hospital in Fiji-A Pilot Study.
| Τίτλος: | Efficacy of 'Triple Therapy' in Eradicating Ulcer Related Helicobacter pylori Infection at a Tertiary Hospital in Fiji-A Pilot Study. |
|---|---|
| Συγγραφείς: | Kumar VV; Department in Internal Medicine, Labasa Hospital, Labasa, Fiji., Paterson C; Department of Surgery, Te Whatu Ora - Counties Manukau, University of Auckland, Auckland, New Zealand., Hill A; Department of Surgery, Te Whatu Ora - Counties Manukau, University of Auckland, Auckland, New Zealand., Sharma V; Faculty of Internal Medicine, Fiji National University, Suva, Fiji. |
| Πηγή: | ANZ journal of surgery [ANZ J Surg] 2025 Sep; Vol. 95 (9), pp. 1745-1749. Date of Electronic Publication: 2025 Jun 23. |
| Τύπος έκδοσης: | Journal Article; Observational Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Publishing Asia Country of Publication: Australia NLM ID: 101086634 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1445-2197 (Electronic) Linking ISSN: 14451433 NLM ISO Abbreviation: ANZ J Surg Subsets: MEDLINE |
| Imprint Name(s): | Publication: Carlton, Victoria, Australia : Wiley-Blackwell Publishing Asia Original Publication: Carlton, Victoria, Australia : Blackwell Science Asia on behalf of the Royal Australasian College of Surgeons, c2001- |
| Ιατρικοί όροι (MeSH): | Helicobacter Infections*/drug therapy , Helicobacter Infections*/diagnosis , Helicobacter Infections*/complications , Helicobacter pylori*/isolation & purification , Clarithromycin*/administration & dosage , Clarithromycin*/therapeutic use , Anti-Bacterial Agents*/therapeutic use , Anti-Bacterial Agents*/administration & dosage , Peptic Ulcer*/drug therapy , Peptic Ulcer*/microbiology , Proton Pump Inhibitors*/therapeutic use , Proton Pump Inhibitors*/administration & dosage, Amoxicillin/therapeutic use ; Amoxicillin/administration & dosage ; Metronidazole/therapeutic use ; Metronidazole/administration & dosage ; Humans ; Male ; Female ; Pilot Projects ; Prospective Studies ; Middle Aged ; Fiji ; Drug Therapy, Combination ; Tertiary Care Centers ; Treatment Outcome ; Adult ; Gastroscopy ; Aged |
| Περίληψη: | Background: Fiji currently uses a seven-day Clarithromycin based triple therapy regimen for Heliobacter pylori (H. pylori) eradication, and the local eradication rate is unknown. H. pylori testing is performed using a rapid urease test (RUT) during gastroscopy in Fiji. Methods: A year-long prospective observational study was undertaken at the Colonial War Memorial Hospital in Fiji. Eligible participants included patients who had peptic ulcer disease (PUD) on gastroscopy and a positive RUT. Consenting participants were prescribed Clarithromycin based triple therapy for 7 days, and underwent a second gastroscopy with RUT after 6 to 8 weeks. Participants who tested positive on a repeat RUT received Clarithromycin based triple therapy for 14 days, and underwent a third gastroscopy and RUT. Participants who remained positive for H. pylori were prescribed quadruple therapy for 14 days. Results: Forty-nine patients were enrolled in the study. Thirty-six (73.5%) had a negative RUT after a seven-day Clarithromycin-based regimen. Eleven of the 13 participants who remained positive eradicated H. pylori after being given another course of the same regimen for 14 days, resulting in a final eradication rate of 95.9%. The remaining two participants received quadruple therapy for 14 days. Conclusion: This study demonstrates an eradication rate of 73.5% using a seven-day Clarithromycin-based regimen in Fiji among H. pylori positive patients with PUD on gastroscopy. This was significantly improved using a 14-day regimen. H. pylori has reduced susceptibility to the current seven-day Clarithromycin based regimen. Future local guidelines should extend to 14 days to achieve a greater eradication rate. (© 2025 Royal Australasian College of Surgeons.) |
| References: | K. E. McColl, “Clinical Practice. Helicobacter Pylori Infection,” New England Journal of Medicine 362, no. 17 (2010): 1597–1604. S. F. Moss, “The Clinical Evidence Linking Helicobacter Pylori to Gastric Cancer,” Cellular and Molecular Gastroenterology and Hepatology 3, no. 2 (2016): 183–191. IARC, Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100B. A Review of Human Carcinogens (Lyon, 2012). A. Savoldi, E. Carrara, D. Y. Graham, M. Conti, and E. Tacconelli, “Prevalence of Antibiotic Resistance in helicobacter pylori: A Systematic Review and Meta‐Analysis in World Health Organization Regions,” Gastroenterology 155, no. 5 (2018): 1372–1382. W. D. Chey, G. I. Leontiadis, C. W. Howden, and S. F. Moss, “ACG Clinical Guideline: Treatment of helicobacter pylori Infection,” American Journal of Gastroenterology 112, no. 2 (2017): 212–239. V. De Francesco, A. Bellesia, L. Ridola, R. Manta, and A. Zullo, “First‐Line Therapies for Helicobacter pylori Eradication: A Critical Reappraisal of Updated Guidelines,” Annals of Gastroenterology 30, no. 4 (2017): 373–379. National Therapeutics and Drug Subcommittee, “Antibiotic Guidelines,” in Ministry of Health and Medical Services, Government of Fiji (Ministry of Health and Meidcal Serves, 2019), 205. Y. Yuan, A. C. Ford, K. J. Khan, et al., “Optimum Duration of Regimens for Helicobacter Pylori Eradication,” Cochrane Database of Systematic Reviews 12 (2013): CD008337. R. N. Naidu, “The Prevalence of Helicobacter Pylori Infection in Patients Undergoing Endoscopy at the Colonial War Memorial Hospital from January 2011 to January 2013. [Master's Thesis],” College of Medicine Nursing and Health Science 1 (2013): 11–18. P. H. Katelaris, D. G. Lowe, P. Norbu, and M. J. Farthing, “Field Evaluation of a Rapid, Simple and Inexpensive Urease Test for the Detection of Helicobacter Pylori,” Journal of Gastroenterology and Hepatology 7, no. 6 (1992): 569–571. Y. Hu, Y. Zhu, and N. H. Lu, “Novel and Effective Therapeutic Regimens for helicobacter pylori in an Era of Increasing Antibiotic Resistance,” Frontiers in Cellular and Infection Microbiology 7 (2017): 168. “Helicobacter pylori Infection In: eTG complete [Internet]. Melbourne,” 2016. |
| Contributed Indexing: | Keywords: Helicobacter pylori; Fiji; eradication; peptic ulcer disease; resistance |
| Substance Nomenclature: | H1250JIK0A (Clarithromycin) 0 (Anti-Bacterial Agents) 804826J2HU (Amoxicillin) 0 (Proton Pump Inhibitors) 140QMO216E (Metronidazole) |
| Entry Date(s): | Date Created: 20250623 Date Completed: 20251001 Latest Revision: 20260722 |
| Update Code: | 20260722 |
| DOI: | 10.1111/ans.70231 |
| PMID: | 40548480 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1445-2197 |
|---|---|
| DOI: | 10.1111/ans.70231 |